Hofseth BioCare ASA (HOFBF)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 280.78 Million USD | 2544.01% |
| 2022 | 10.61 Million NOK | -32.63% |
| 2021 | 15.76 Million NOK | 33.84% |
| 2020 | 11.77 Million NOK | -21.87% |
| 2019 | 15.07 Million NOK | -74.95% |
| 2018 | 60.17 Million NOK | -26.1% |
| 2017 | 81.42 Million NOK | 9.38% |
| 2016 | 74.44 Million NOK | -24.52% |
| 2015 | 98.62 Million NOK | -1.78% |
| 2014 | 100.41 Million NOK | 3.89% |
| 2013 | 96.65 Million NOK | 41.03% |
| 2012 | 68.53 Million NOK | 190.73% |
| 2011 | 23.57 Million NOK | 179.55% |
| 2010 | 8.43 Million NOK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 15.85 Million USD | 4.23% |
| 2024 Q1 | 15.02 Million USD | 18.86% |
| 2023 Q2 | 9.43 Million USD | -2.2% |
| 2023 Q3 | 9.29 Million USD | -1.43% |
| 2023 Q4 | 13.42 Million USD | 44.47% |
| 2023 Q1 | 9.64 Million USD | -9.2% |
| 2023 FY | 280.78 Million USD | 2544.01% |
| 2022 Q4 | 10.61 Million NOK | 8.55% |
| 2022 Q1 | 15.39 Million NOK | -2.34% |
| 2022 Q2 | 16.1 Million NOK | 4.62% |
| 2022 Q3 | 9.78 Million NOK | -39.25% |
| 2022 FY | 10.61 Million NOK | -32.63% |
| 2021 Q1 | 11.44 Million NOK | -88.65% |
| 2021 FY | 15.76 Million NOK | 33.84% |
| 2021 Q2 | 14.93 Million NOK | 30.48% |
| 2021 Q4 | 15.76 Million NOK | -1.52% |
| 2021 Q3 | 16 Million NOK | 7.19% |
| 2020 FY | 11.77 Million NOK | -21.87% |
| 2020 Q1 | 114.6 Million NOK | -15.39% |
| 2020 Q2 | 144.07 Million NOK | 25.72% |
| 2020 Q3 | 142.31 Million NOK | -1.22% |
| 2020 Q4 | 100.84 Million NOK | -29.14% |
| 2019 Q4 | 135.44 Million NOK | -1.69% |
| 2019 Q1 | 125.76 Million NOK | 108.99% |
| 2019 Q2 | 121.49 Million NOK | -3.39% |
| 2019 FY | 15.07 Million NOK | -74.95% |
| 2019 Q3 | 137.77 Million NOK | 13.4% |
| 2018 Q3 | 56.16 Million NOK | -24.64% |
| 2018 Q2 | 74.52 Million NOK | 12.88% |
| 2018 Q1 | 66.02 Million NOK | -18.91% |
| 2018 FY | 60.17 Million NOK | -26.1% |
| 2018 Q4 | 60.17 Million NOK | 7.14% |
| 2017 Q4 | 81.42 Million NOK | 101.41% |
| 2017 Q3 | 40.42 Million NOK | 22.16% |
| 2017 Q2 | 33.09 Million NOK | -48.58% |
| 2017 FY | 81.42 Million NOK | 9.38% |
| 2017 Q1 | 64.35 Million NOK | -13.55% |
| 2016 Q4 | 74.44 Million NOK | -12.19% |
| 2016 FY | 74.44 Million NOK | -24.52% |
| 2016 Q3 | 84.77 Million NOK | -30.6% |
| 2016 Q2 | 122.16 Million NOK | 23.33% |
| 2016 Q1 | 99.05 Million NOK | 0.44% |
| 2015 Q2 | 122.97 Million NOK | 15.66% |
| 2015 FY | 98.62 Million NOK | -1.78% |
| 2015 Q3 | 113.01 Million NOK | -8.1% |
| 2015 Q1 | 106.33 Million NOK | 5.89% |
| 2015 Q4 | 98.62 Million NOK | -12.74% |
| 2014 Q1 | 98.57 Million NOK | 1.99% |
| 2014 FY | 100.41 Million NOK | 3.89% |
| 2014 Q4 | 100.41 Million NOK | 15.93% |
| 2014 Q2 | 84.45 Million NOK | -14.33% |
| 2014 Q3 | 86.61 Million NOK | 2.56% |
| 2013 Q4 | 96.65 Million NOK | 9.19% |
| 2013 Q3 | 88.51 Million NOK | 12.18% |
| 2013 FY | 96.65 Million NOK | 41.03% |
| 2013 Q2 | 78.9 Million NOK | -13.82% |
| 2013 Q1 | 91.56 Million NOK | 33.61% |
| 2012 Q1 | 23.47 Million NOK | -0.4% |
| 2012 FY | 68.53 Million NOK | 190.73% |
| 2012 Q2 | 33.15 Million NOK | 41.24% |
| 2012 Q4 | 68.53 Million NOK | 10.44% |
| 2012 Q3 | 62.04 Million NOK | 87.13% |
| 2011 FY | 23.57 Million NOK | 179.55% |
| 2011 Q3 | 23.3 Million NOK | 0.0% |
| 2011 Q4 | 23.57 Million NOK | 1.13% |
| 2010 FY | 8.43 Million NOK | 0.0% |
| 2010 Q4 | 8.43 Million NOK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -581.477% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -6712.031% |
| SQZ Biotechnologies Company | 27.47 Million USD | -922.129% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -547.382% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -843.285% |
| Mesoblast Limited | 118.7 Million USD | -136.553% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -29510.628% |
| Genus plc | 233.1 Million USD | -20.459% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -9481.973% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -20798.507% |
| Marizyme, Inc. | 18.71 Million USD | -1400.142% |
| ContraFect Corporation | 2.88 Million USD | -9646.234% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -37338.533% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -207144.237% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -19314.044% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -11971.988% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -4862.38% |
| MultiCell Technologies, Inc. | 202.58 USD | -138606376.454% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -388.422% |
| EV Biologics, Inc. | 1.49 Million USD | -18685.002% |
| Q BioMed Inc. | 4.1 Million USD | -6731.881% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -748.28% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -44464.236% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -22758.834% |
| Biomind Labs Inc. | 735.54 Thousand USD | -38074.435% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | -63.682% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -2060.415% |
| Skye Bioscience, Inc. | 4.61 Million USD | -5983.918% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -31518.104% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -198312.216% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -4682.57% |
| IMV Inc. | 28.88 Million USD | -872.13% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1091657.067% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -12333.199% |
| GB Sciences, Inc. | 1.75 Million USD | -15860.205% |
| Alpha Cognition Inc. | 1.22 Million USD | -22908.476% |
| HST Global, Inc. | 98.31 Thousand USD | -285489.764% |
| CSL Limited | 12.18 Billion USD | 97.695% |
| Halberd Corporation | 150 Thousand USD | -187092.667% |
| Enzolytics Inc. | 996.33 Thousand USD | -28082.103% |
| Resverlogix Corp. | 6.49 Million USD | -4225.82% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -58703.979% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -109758.29% |
| argenx SE | 20 Million USD | -1303.945% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -516.306% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -10266.179% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2746002.689% |
| Genscript Biotech Corporation | 417.73 Million USD | 32.784% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -139863.413% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -11610.647% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -122359.669% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -315.105% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -9178.628% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -77959.826% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -1281.292% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -188787.618% |
| BioStem Technologies, Inc. | 4.71 Million USD | -5859.757% |
| ONE Bio Corp. | 19.71 Million USD | -1324.239% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -112133.894% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -112793.615% |
| Agentix Corp. | 50 Thousand USD | -561478.0% |
| LadRx Corporation | 33.6 Thousand USD | -835432.345% |
| Cell Source, Inc. | 9.25 Million USD | -2934.188% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -37031.383% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -37031.383% |
| NovAccess Global Inc. | 2.19 Million USD | -12663.833% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -3869.978% |
| Itoco Inc. | 228.37 Thousand USD | -122849.772% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -132991.125% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -5534.939% |
| Kadimastem Ltd | 891.22 Thousand USD | -31405.926% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -69774.256% |
| CytoDyn Inc. | 30.07 Million USD | -833.598% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -57880.235% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -79704.29% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -3490.671% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -229115.51% |
| Rebus Holdings, Inc. | 310 Thousand USD | -90477.097% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -5829.721% |
| International Stem Cell Corporation | 4.17 Million USD | -6620.656% |
| Bioxytran, Inc. | 1.92 Million USD | -14486.442% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -449788.645% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -12774.914% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -3276.491% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -3170.693% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -17951.61% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -104672.015% |
| Neutra Corp. | 54.15 Thousand USD | -518381.793% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -15243.661% |
| PureTech Health plc | 25.51 Million USD | -1000.615% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -22836.043% |
| IXICO plc | 472.02 Thousand USD | -59386.296% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -1711.425% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -350.972% |
| CSL Limited | 12.18 Billion USD | 97.695% |
| Cellectis S.A. | 92.77 Million USD | -202.651% |